Recent Updates
Recently added Catalysts

Hydrocodone/Acetaminophen

Phase 2

Pain | Small molecule | Pain |Abbott Laboratories|Last Updated: Jan 19, 2011

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment120
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00404183A Study Comparing the Analgesic Efficacy and Safety of Extended Release Hydrocodone/Acetaminophen (Vicodin® CR)and Placebo in Subjects With OsteoarthritisPHASE2 COMPLETED 120Aug 1, 2004 -Jan 19, 2011 -
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Pain intensity difference from baseline to final assessment using the VAS scale (100 mm, 0 being "no pain" and 100 being "worst pain imaginable").
4 weeks

Arthritis Pain Intensity measured by a 100mm Visial Analog Scase (VAS)

Secondary Endpoints
WOMAC Osteoarthritis Index, SF36
4 weeks
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
hydrocodone/acetaminophen extended releaseEXPERIMENTAL -
PlaceboPLACEBO_COMPARATOR -
Interventions
NameTypeDescription
Extended-Release Hydrocodone/AcetaminophenDRUG2 tablets BID
PlaceboDRUG2 tablets BID
Unlock Study Design Details
Eligibility Criteria
Age Range21 Years — 75 Years
SexALL
Healthy VolunteersNo

Inclusion Criteria: * Males or females ages 21 to 75 * Has osteoarthritis of the hip or knee * Requires therapeutic doses of medications for osteoarthritis * If female, must be of non-childbearing potential or practicing birth control * Has sufficient pain to justify the use of round-the-clock opio...

Unlock Eligibility Criteria